CANCER GENE THERAPY

Scope & Guideline

Pioneering Research in Cancer Gene Therapy

Introduction

Delve into the academic richness of CANCER GENE THERAPY with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN0929-1903
PublisherSPRINGERNATURE
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1994 to 2024
AbbreviationCANCER GENE THER / Cancer Gene Ther.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Aims and Scopes

The journal 'CANCER GENE THERAPY' is dedicated to advancing the field of cancer research through gene therapy approaches. It covers a wide spectrum of topics related to genetic and epigenetic mechanisms underlying cancer, innovative therapeutic strategies, and the evaluation of novel gene therapy applications.
  1. Gene Therapy Innovations:
    Focus on the development and application of various gene therapy techniques, including oncolytic viruses, CAR-T cell therapies, and RNA-based therapeutics.
  2. Molecular Mechanisms and Pathways:
    In-depth exploration of the molecular pathways involved in cancer progression, treatment resistance, and the role of genetic modifications.
  3. Tumor Microenvironment Interactions:
    Investigation of how the tumor microenvironment influences cancer progression and response to therapies, including the role of extracellular vesicles and immune cells.
  4. Biomarker Discovery and Validation:
    Identification and validation of biomarkers for cancer diagnosis, prognosis, and therapeutic response, facilitating personalized medicine approaches.
  5. Translational Research:
    Emphasis on translating laboratory findings into clinical applications, including clinical trials of gene therapy techniques and their effectiveness in cancer treatment.
Recent publications indicate a dynamic evolution in the focus areas of 'CANCER GENE THERAPY', with several themes gaining traction and reflecting the current trends in cancer research.
  1. RNA Modifications and Non-coding RNAs:
    Emerging studies highlight the roles of RNA modifications (e.g., m6A) and non-coding RNAs (e.g., circRNAs, lncRNAs) in cancer biology, signaling pathways, and potential therapeutic targets.
  2. Immunotherapy and Tumor Microenvironment Modulation:
    Increased focus on immunotherapy strategies, including CAR-T cell therapies and immune checkpoint inhibitors, as well as the role of the tumor microenvironment in modulating immune responses.
  3. Synthetic Lethality Approaches:
    Research on synthetic lethality is gaining attention, particularly in the context of targeting specific genetic vulnerabilities in cancer cells, offering new therapeutic strategies.
  4. Targeted Therapy Combinations:
    A notable trend towards investigating the efficacy of combination therapies that target multiple pathways or mechanisms simultaneously to overcome resistance and improve patient outcomes.
  5. Personalized and Precision Medicine:
    Research is increasingly oriented towards personalized medicine, emphasizing the need for tailored therapies based on individual genomic and molecular profiles.

Declining or Waning

While the journal continues to explore a broad range of topics, certain research areas have shown a decline in focus or publication frequency, suggesting shifts in research priorities or emerging interests.
  1. Traditional Chemotherapy Approaches:
    Research related to conventional chemotherapy is less frequently addressed, as the field shifts towards targeted therapies and personalized medicine.
  2. Basic Cancer Biology without Therapeutic Focus:
    Studies focusing solely on basic cancer biology without implications for therapeutic development are becoming less prominent in favor of research with direct clinical applications.
  3. Single-Agent Therapies:
    There is a waning interest in studies evaluating single-agent therapies, as combination therapies and multi-targeted approaches are increasingly favored.
  4. Epidemiological Studies:
    Epidemiological research related to cancer incidence and prevalence is less frequently published, with a greater emphasis on mechanistic and therapeutic studies.

Similar Journals

CYTOTHERAPY

Advancing the Future of Cell Therapy.
Publisher: ELSEVIER SCI LTDISSN: 1465-3249Frequency: 12 issues/year

CYTOTHERAPY is a distinguished journal published by Elsevier Science Ltd, focusing on the critical fields of cell therapy, transplantation, and regenerative medicine. Since its inception in 1999, the journal has established itself as a vital resource for researchers and practitioners, contributing significantly to advancements in Cancer Research, Cell Biology, Genetics, Immunology, and Oncology. With an impressive range of Q2 rankings across multiple categories and a remarkable Q1 standing in Transplantation for 2023, CYTOTHERAPY delivers high-impact research that addresses the evolving challenges in these fields. While the journal does not offer open access, it remains a reputable avenue for disseminating pivotal studies and reviews that push the boundaries of cell-based therapies. Researchers, clinicians, and students alike will find CYTOTHERAPY an indispensable platform to stay abreast of the latest discoveries and innovations that are shaping the future of medical science.

HEMATOLOGICAL ONCOLOGY

Shaping the Future of Cancer Treatment and Research
Publisher: WILEYISSN: 0278-0232Frequency: 4 issues/year

HEMATOLOGICAL ONCOLOGY, published by Wiley, is a premier journal in the fields of cancer research, hematology, and oncology, with a rich history of publication dating back to 1983. With an impact factor indicative of its influential standing—ranking in the second quartile in multiple categories including Cancer Research, Hematology, and Oncology—this journal serves as a vital resource for researchers, clinicians, and students alike. HEMATOLOGICAL ONCOLOGY is based in the United Kingdom and focuses on the advancements and challenges in the understanding and treatment of hematological malignancies. While it does not offer open access options, its rigorous peer-review process ensures that all published articles are of the highest quality, contributing to the ongoing dialogue and research in this critical area of medicine. With its commitment to disseminating impactful research, HEMATOLOGICAL ONCOLOGY remains an essential platform for driving innovation and collaboration within the global scientific community.

JOURNAL OF GENE MEDICINE

Advancing the Frontiers of Gene Therapy
Publisher: WILEYISSN: 1099-498XFrequency: 12 issues/year

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

Molecular & Cellular Oncology

Unraveling the complexities of cancer biology.
Publisher: TAYLOR & FRANCIS INCISSN: Frequency: 6 issues/year

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

MOLECULAR THERAPY

Transforming drug discovery with cutting-edge research.
Publisher: CELL PRESSISSN: 1525-0016Frequency: 12 issues/year

MOLECULAR THERAPY, published by CELL PRESS, is a distinguished journal in the field of molecular biology and therapy, renowned for its significant contributions to drug discovery, genetics, and pharmacology since its inception in 2000. This prestigious journal, which holds a commendable position in the Q1 category across multiple disciplines including Drug Discovery, Molecular Medicine, and Molecular Biology, facilitates cutting-edge research and innovative therapies that aim to improve patient outcomes. With an impressive Scopus ranking that places it among the top journals in its field—such as rank #6 in Drug Discovery and #8 in Pharmacology—MOLECULAR THERAPY is crucial for researchers, professionals, and students seeking to advance their understanding and application of molecular techniques. The journal welcomes high-quality submissions that explore the therapeutic potential of molecular mechanisms, fostering a collaborative spirit within the scientific community to push the boundaries of modern medicine.

Oncologie

Exploring innovative solutions in oncology.
Publisher: WALTER DE GRUYTER GMBHISSN: 1292-3818Frequency: 6 issues/year

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

EXPERT REVIEWS IN MOLECULAR MEDICINE

Pioneering Reviews that Drive Molecular Research Forward
Publisher: CAMBRIDGE UNIV PRESSISSN: 1462-3994Frequency: 1 issue/year

EXPERT REVIEWS IN MOLECULAR MEDICINE, published by Cambridge University Press, stands at the forefront of research in the fields of Molecular Biology and Molecular Medicine. With an impressive impact factor reflecting its Q1 status in both relevant categories, this journal serves as an essential platform for disseminating cutting-edge reviews and critical assessments that are vital for advancing our understanding of molecular mechanisms in health and disease. Established in 1997 and continuously evolving until 2024, it features contributions from leading experts that highlight emerging trends and innovative methodologies. Researchers, professionals, and students are encouraged to engage with the content, benefiting from the journal’s rigorous peer-review process and its commitment to academic excellence, making it a valuable resource within the scientific community.

Molecular Therapy Oncolytics

Empowering Researchers to Revolutionize Cancer Therapy
Publisher: CELL PRESSISSN: 2372-7705Frequency: 1 issue/year

Molecular Therapy Oncolytics is an esteemed Open Access journal published by CELL PRESS, focusing on cutting-edge research in the fields of oncology, molecular medicine, and pharmacology. Established in 2014, the journal has quickly gained a prominent position in the academic community, reflected in its impressive Q1 and Q2 rankings across various categories including Cancer Research, Molecular Medicine, and Pharmacology. With an impactful presence in the UK and a strong international readership, it aims to disseminate significant advancements in therapeutic strategies targeted at cancer treatment and management. By providing a platform for peer-reviewed research, Molecular Therapy Oncolytics plays a critical role in bridging the gap between scientific innovation and clinical application, making it an invaluable resource for researchers, healthcare professionals, and students striving to contribute to the evolving landscape of oncology.

Journal of Gastrointestinal Oncology

Advancing knowledge in gastrointestinal cancer research.
Publisher: AME PUBLISHING COMPANYISSN: 2078-6891Frequency: 6 issues/year

The Journal of Gastrointestinal Oncology, published by AME Publishing Company, is a leading open-access journal that focuses on the complex interplay between gastroenterology and oncology. Established in 2012 and converging into a reputable academic platform through 2024, the journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements in the diagnosis, treatment, and management of gastrointestinal cancers. With an ISSN of 2078-6891 and an E-ISSN of 2219-679X, this journal presents articles that are rigorously peer-reviewed, ensuring high-quality content that meets the demands of the scientific community. Despite its current categorization in the Q3 quartile for both Gastroenterology and Oncology as of 2023, it consistently strives to improve its impact and relevance, reflected in its Scopus rankings and percentile metrics. Publishing noteworthy research, reviews, and case studies, the Journal of Gastrointestinal Oncology is instrumental in addressing significant challenges in the field, making it a must-read for those dedicated to advancing knowledge and practice in gastrointestinal oncology.

HUMAN GENE THERAPY

Advancing Innovations in Gene Therapy
Publisher: MARY ANN LIEBERT, INCISSN: 1043-0342Frequency: 12 issues/year

Human Gene Therapy, an esteemed journal published by Mary Ann Liebert, Inc., is at the forefront of the rapidly evolving fields of genetics, molecular biology, and molecular medicine. With a significant impact in its domain, it is categorized in the Q2 quartile across multiple disciplines, reflecting its commitment to disseminating high-quality, impactful research. Established in 1990, the journal has continuously provided a vital platform for scientists and practitioners to explore groundbreaking developments in gene therapy, genetic engineering, and related technologies. With a focus on peer-reviewed articles that foster advancements in therapeutic applications, Human Gene Therapy serves not only as a comprehensive resource for academia but also as an essential reference for professionals engaged in genetic research and clinical practice. Although currently not open access, the journal remains a crucial source of knowledge, driving innovation and collaboration within the gene therapy community.